The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.Source: electronic medicines compendium (emc), DatapharmActive substance: cinchocaine hydrochloride, prednisolone hexanoateOfficial document: view the original leaflet on emc →Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

← Back to all medicines

Scheriproct Suppositories

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Cinchocaine hydrochloride, Prednisolone hexanoate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Cinchocaine hydrochloride, Prednisolone hexanoate

Source: electronic medicines compendium (emc)

Official leaflet: Read the PIL on emc

What it is and what it is used for

for Scheriproct contains a substance which reduces inflammation (prednisolone) and a local anaesthetic (cinchocaine) which relieves pain. This medicine is used for the relief of the inflammation, swelling, itching and soreness of piles (haemorrhoids) and to relieve itching of the anus (back passage). It is used short-term usually for 5 to 7 days. Corticosteroid creams, ointments and other topical preparations come in four different potencies or strengths. These are known as mild, moderately potent, potent or very potent. Healthcare professionals will usually refer to topical corticosteroid potency rather than strength. A potent or strong corticosteroid has a much stronger effect than a mild corticosteroid when using the same amount. The percentage of active ingredient that is sometimes included on product packaging does not indicate potency. Scheriproct is classed as a mild corticosteroid. Your healthcare professional will prescribe or advise a steroid of the appropriate potency for your condition.

What you need to know before you take it

e Scheriproct® Do not use Scheriproct: • if you are allergic to prednisolone hexanoate, cinchocaine hydrochloride, other local anaesthetics or any of the other ingredients of this medicine (listed in section 6). • if you have a viral infection (e.g. herpes, shingles, chicken-pox). • if you have any bacterial or fungal infections of the skin or elsewhere for which you are not receiving treatment.

Warnings and precautions Talk to your doctor or pharmacist before using Scheriproct • Long-term continuous treatment should be avoided because it increases the possibility of side effects. This is particularly important for infants and small children because continuous treatment with Scheriproct for long periods may reduce the activity of the adrenal glands and so lower resistance to disease. Also, long-term treatment can cause the skin to thin and deteriorate in the affected area (see section 4) and some of the medicine may be absorbed into the blood stream. • If the area treated with Scheriproct is also infected your doctor should prescribe another medicine, to use with Scheriproct, to treat the infection. • Do not use a waterproof dressing to cover areas where you have applied the ointment. • In case latex products such as condoms are used concomitantly in the area of treatment with Scheriproct its ingredient(s) may cause damage to those latex products. Therefore, these may no longer be effective as contraception or as protection against sexually transmitted diseases such as HIV infection. Talk to your doctor or pharmacist, if you require more information. • Contact your doctor if you experience blurred vision or other visual disturbances. Other medicines and Scheriproct Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may increase the effects of Scheriproct and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There may be a very small risk to the development of a baby in pregnant women treated with Scheriproct. As with most medicines, this risk is likely to be greatest during the first 3 months of pregnancy.

Driving and using machines Scheriproct has no influence on the ability to drive and use machines. Scheriproct ointment contains castor oil, castor oil hydrogenated and macrogol 400 monoricinoleate that may cause skin reactions. 3. How to use Scheriproct® Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not use Scheriproct for more than 7 days. Always wash your hands before and after applying Scheriproct. How to use Scheriproct Ointment: 1. 2.

Before you use the ointment, gently but thoroughly wash and dry the anus (back passage) and the skin around it. If the ointment is to be used for the area around the anus:

Squeeze a small quantity (about the size of a pea) on to the top of your finger.
Spread it gently over the skin and just inside the anus.
Do not rub it in. If the ointment is to be used inside the anus:
Screw the separate applicator completely onto the tube. Do not use the applicator if damaged.
Squeeze the tube until the applicator is full of ointment. The amount of ointment in the applicator is one dose.
Insert the applicator very carefully into the anus until the whole length of the applicator is inside.
Then, while squeezing the tube gently, withdraw the applicator.
After each use, clean externally the applicator with a paper towel, then remove the remaining product in the applicator with a cotton swab and clean it again with a paper towel. Rinse the applicator under warm water for about 1 minute and dry externally the applicator with a paper towel.

Generally, the ointment should be applied twice a day, but it may be applied three or four times on the first day, to obtain quick relief.

How to take it

Scheriproct Suppositories: 1. Before you insert a suppository find the small tear in the foil packet and remove the covering foil, by tearing it in half. 2. If the suppositories have become softened, owing to warm temperature, they can be hardened by putting them into cold water before you remove the covering foil. 3. Insert the whole suppository into the anus. 4. To make insertion easier, either stand with one foot raised on a chair or squat down. 3

The usual treatment is one suppository a day, to be inserted preferably after a bowel movement. However, if your discomfort is severe, you should insert one suppository two or three times a day at the start of treatment. If you use more Scheriproct than you should or if you accidentally swallow some Scheriproct If you use too much Scheriproct or accidentally swallow Scheriproct it is unlikely to be dangerous but contact your doctor or pharmacist if you are worried. If you forget to use Scheriproct Do not use a double dose to make up for a forgotten dose. When you remember, use the next prescribed dose and continue with the treatment. See your doctor or pharmacist, if you are worried. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Some thinning of the skin may occur if too much Scheriproct is applied for long periods of time (much longer than 5 to 7 days). Allergic skin reactions may occur in rare cases. Castor oil, one of the ingredients of Scheriproct Ointment may cause a skin reaction. You must get urgent medical help if you have any of the following symptoms. You may be having an allergic reaction. This is rare and may affect up to 1 in 1,000 people:

Angioedema (rapid swelling under the skin)
Eye swelling
Swelling face
Dyspnoea (shortness of breath) Not known (frequency cannot be estimated from the available data): Blurred vision. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Scheriproct® • • • • •

Keep this medicine out of the sight and reach of children. Do not store Scheriproct Ointment above 25oC. Store Scheriproct Suppositories in a refrigerator (2C to 8C). Do not use Scheriproct after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Scheriproct Ointment contains • The active substances are prednisolone hexanoate and cinchocaine hydrochloride. 1 g of Scheriproct Ointment contains 1.9 mg prednisolone hexanoate and 5.0 mg cinchocaine hydrochloride • The other ingredients are macrogol-400-monoricinoleate, castor oil, hydrogenated, castor oil, refined, 2 octyldodecanol. What Scheriproct Suppositories contain • The active substances are prednisolone hexanoate and cinchocaine hydrochloride. Each suppository contains 1.3 mg prednisolone hexanoate and 1.0 mg cinchocaine hydrochloride • The other ingredient is hard fat. What Scheriproct looks like and contents of the pack • Scheriproct Ointment is a colourless to slightly yellowish ointment supplied in tubes of 30 g with a separate applicator. • Scheriproct Suppositories are yellowish-white and are supplied in packs of 12 suppositories. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Karo Pharma AB Box 16184 103 24 Stockholm Sweden Manufacturer The ointment is manufactured by: LEO Pharma Manufacturing Italy S.r.l. Via E. Schering 21 20054 Segrate (Milan) Italy

Temmler Italia S.r.l.,Carugate, Italy Via Delle Industrie 2, Carugate, 20061, Italy The suppositories are manufactured by: Istituto de Angeli S.r.l. Località Prulli, 103/C 50060 Reggello (Florence) Italy This leaflet was last revised in October 2025.

Frequently asked questions about Scheriproct Suppositories

How do I take Scheriproct Suppositories?

Scheriproct Suppositories comes as suppository. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Scheriproct Suppositories?

The active substance in Scheriproct Suppositories is cinchocaine hydrochloride, prednisolone hexanoate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Scheriproct Suppositories, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Scheriproct Suppositories without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Source: electronic medicines compendium (emc), Datapharm
Active substance: cinchocaine hydrochloride, prednisolone hexanoate
Official document: view the original leaflet on emc →

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Cinchocaine hydrochloride, prednisolone hexanoate (2 medicines)

See every medicine containing this substance, or browse the full A–Z of active substances.

⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+

Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

For the symptomatic relief of haemorrhoids and pruritus ani in the short term (5-7 days).

4.2. Posology and method of administration

One Scheriproct suppository to be inserted daily. In severe cases one suppository two to three times daily at the beginning of treatment. The suppositories should be inserted after defaecation.

4.3. Contraindications

Viral infections. Primary bacterial or fungal infections. Secondary infections of the skin in the absence of appropriate anti-infective therapy. Known sensitivity to local anaesthetics.

4.4. Special warnings and precautions for use

Warnings: In infants, long-term continuous therapy with topical corticosteroids should be avoided. Occlusion is not appropriate on the perineum. Adrenal suppression can occur, even without occlusion. As with all topical steroids, there is a risk of developing skin atrophy following extensive therapy. The application of unusually large quantities of topical corticoids may result in the absorption of systemically active amounts of corticoid. Secondarily infected dermatoses definitely require additional therapy with antibiotics or chemotherapeutic agents. This treatment can often be topical, but for heavy infections systemic antibacterial therapy may be necessary. If fungal infections are present, a topically active antimycotic should be applied.

The excipient (hard fat) in Scheriproct suppositories may reduce the effectiveness of latex products such as condoms.

Visual disturbance:

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

The label will state mild steroid.

4.5. Interaction with other medicinal products and other forms of interaction

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.

4.6. Fertility, pregnancy and lactation

Pregnancy

There is inadequate evidence of safety in human pregnancy. Epidemiological studies suggest that there could possibly be an increased risk of oral clefts among newborns of women who were treated with glucocorticoids during the first trimester of pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intrauterine growth retardation. There may therefore be a very small risk of such effects on the human foetus. Also, hypoadrenalism may occur in the neonate. In general, the use of topical preparations containing glucocorticoids should be avoided during the first trimester of pregnancy. The clinical indication for treatment with Scheriproct must be carefully reviewed and the benefits weighed against the risks in pregnant and lactating women. In particular, prolonged use must be avoided. When corticosteroids are essential however, patients with normal pregnancies may be treated as though they were in the non-gravid state. Patients with pre-eclampsia or fluid retention require close monitoring.

Breast-feeding

Corticosteroids are excreted in small amounts in breast milk and infants of mothers taking pharmacological doses of steroids should be monitored carefully for signs of adrenal suppression.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

As with all topical steroids, there is a risk of developing skin atrophy following extensive therapy. Allergic skin reactions may occur.

Eye disorders

Not known (frequency cannot be estimated from the available data):

Vision, blurred (see also section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

None stated.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

⚠ Not the same combination. This medicine contains Cinchocaine hydrochloride, Prednisolone hexanoate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.

ULTRACORTENOL 5 mg/g prescription partial — not the same combinationPREDNISOLONUM · eye / ear / nose

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako